Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Pharma Astellas Licenses MorphoSys' HuCAL Library

NEW YORK (GenomeWeb News) — Astellas Pharma will use MorphoSys’ HuCAL Gold antibody library in its drug-discovery efforts, MorphoSys said today.
 
Under the agreement, MorphoSys will receive an up-front payment and user fees over the course of the license, which may last up to five years.
 
MorphoSys said it could also receive research funding from preclinical and clinical development of compounds, as well as licensing, milestone, and royalty payments. 
 
Astellas will use the HuCAL library at its facilities in Tsukuba, Japan, and has the option to start antibody projects over the span of the agreement, MorphoSys said.
 
The companies added a collaborative option into the agreement, under which MorphoSys would “generate novel HuCAL antibodies against targets provided by Astellas,” MorphoSys said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.